Michael R Megna sold $369k of KNSA
CHIEF ACCOUNTING OFFICER at Kiniksa Pharmaceuticals, Ltd.. 4,600 shares at an average of $80.30, traded Sep 3, 2026, filed Sep 3, 2026.
Score components
- +15RoleOfficer
- +15Trade size$369k at market
- +5Share of holdings soldSold 14% of holdings
- 0ClusterNo other insider selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001464583-26-000008, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Jul 15, 2026 | AGrant or award Class A Ordinary Share10b5-1 | +279 | $33.50 | $9,347 | 27,697 | 41 d ago |
| Sep 1, 2026 | MOption exercise Class A Ordinary Share10b5-1 | +3,932 | - | - | 31,629 | 41 d ago |
| Sep 1, 2026 | MOption exercise Class A Ordinary Share10b5-1 | +2,558 | - | - | 34,187 | 41 d ago |
| Sep 1, 2026 | MOption exercise Class A Ordinary Share10b5-1 | +2,362 | - | - | 36,549 | 41 d ago |
| Sep 1, 2026 | MOption exercise Class A Ordinary Share10b5-1 | +2,644 | - | - | 39,193 | 41 d ago |
| Sep 1, 2026 | FTax withholding Class A Ordinary Share10b5-1 | -5,531 | $79.28 | $438k | 33,662 | 41 d ago |
| Sep 3, 2026 | SOpen-market sale Class A Ordinary Share10b5-1 | -4,600 | $80.30 | $369k | 29,062 | 41 d ago |
| Sep 1, 2026 | AGrant or award Restricted Share Unitderivative10b5-1 | +3,650 | $0.00 | $0 | 3,650 | 41 d ago |
| Sep 1, 2026 | AGrant or award Share Optionderivative10b5-1 | +14,600 | $0.00 | $0 | 14,600 | 41 d ago |
| Sep 1, 2026 | MOption exercise Restricted Share Unitderivative10b5-1 | -2,644 | $0.00 | $0 | 7,931 | 41 d ago |
| Sep 1, 2026 | MOption exercise Restricted Share Unitderivative10b5-1 | -2,362 | $0.00 | $0 | 4,725 | 41 d ago |
| Sep 1, 2026 | MOption exercise Restricted Share Unitderivative10b5-1 | -2,558 | $0.00 | $0 | 2,557 | 41 d ago |
| Sep 1, 2026 | MOption exercise Restricted Share Unitderivative10b5-1 | -3,932 | $0.00 | $0 | 0 | 41 d ago |
Related signals
Other insiders at Kiniksa Pharmaceuticals, Ltd. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 34Weak | KNSAsell Kiniksa Pharmaceuticals, Ltd. | G Bradley Cole director | $299k 3,673 shares | -24% | |
| 30Weak | Kiniksa Pharmaceuticals, Ltd. | John F. Paolini CHIEF MEDICAL OFFICER | $3.1M 58,424 shares | -47% | |
| 50Moderate | Kiniksa Pharmaceuticals, Ltd. | Sanj K Patel CHAIRMAN & CEO | $2.6M 48,565 shares | -100% | |
| 50Moderate | Kiniksa Pharmaceuticals, Ltd. | Sanj K Patel CHAIRMAN & CEO | $26M 508,339 shares | -105% | |
| 35Weak | Kiniksa Pharmaceuticals, Ltd. | Barry D Quart director | $656k 13,099 shares | -51% | |
| 29Weak | Kiniksa Pharmaceuticals, Ltd. | Michael R Megna CHIEF ACCOUNTING OFFICER | $309k 6,625 shares | -19% | |
| 29Weak | Kiniksa Pharmaceuticals, Ltd. | Ross Moat CHIEF OPERATING OFFICER | $80k 1,703 shares | -12% | |
| 20Weak | Kiniksa Pharmaceuticals, Ltd. | Barry D Quart director | $345k 6,901 shares | -35% | |
| 40Moderate | Kiniksa Pharmaceuticals, Ltd. | Sanj K Patel CHAIRMAN & CEO | $364k 7,278 shares | -100% | |
| 15Weak | Kiniksa Pharmaceuticals, Ltd. | Ross Moat CHIEF OPERATING OFFICER | $115k 2,367 shares | -16% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.